RIGL — Rigel Pharmaceuticals, Inc.

Summary of Rigel Pharmaceuticals Q1 2026 Earnings Call

1. Key Financial Results and Metrics:

• Net Product Sales: $54.9 million, a 26% increase year-over-year from Q1 2025.
  • TAVALISSE: $37.3 million (31% growth)
  • GAVRETO: $9.6 million (7% growth)
  • REZLIDHIA: $8 million (31% growth)
• Total Revenue: $58.8 million, including $3.9 million from collaborations.
• Net Income: $8.7 million, down from $11.4 million in Q1 2025.
• Cash Position: $146.7 million, down from $155 million at the end of 2025.
• Cost of Sales: Approximately $4.6 million; total expenses increased to $46.9 million from $40.6 million in the prior year.

2. Strategic Updates and Business Highlights:

• Rigel is focused on expanding its product portfolio and advancing its clinical pipeline. The company now has three commercial products and is pursuing in-licensing opportunities for late-stage assets.
• The R289 program for lower-risk MDS is progressing, with data expected by year-end 2026.
• Rigel's growth strategy is built on four pillars: commercial execution, pipeline expansion, clinical development, and financial discipline.
• The company has successfully integrated new products and is exploring larger-scale in-licensing opportunities.

3. Forward Guidance and Outlook:

• Rigel maintains its 2026 revenue guidance of $275 million to $290 million, with net product sales projected between $255 million and $265 million.
• The company anticipates achieving net income profitability for the full year and plans to continue funding clinical development opportunities.

4. Bad News, Challenges, or Points of Concern:

• The collaboration with Lilly for the RIPK1 inhibitor (ocodusertib) will terminate, effective June 15, 2026. This may impact Rigel's strategic focus as it regains rights to the program.
• The plateauing revenue for GAVRETO raises concerns about market competition and the need for increased awareness among prescribers.
• Increased costs in R&D and commercial expenses may pressure profitability despite revenue growth.

5. Notable Q&A Insights:

• Management acknowledged the challenges in growing REZLIDHIA's adoption in community settings, emphasizing the need for effective communication of its benefits in the post-venetoclax treatment landscape.
• Questions about R289 highlighted the importance of safety and efficacy benchmarks for potential FDA registration studies, with management expressing optimism based on preliminary data.
• The sales team noted that community physicians may be hesitant to switch from established treatments, indicating a need for ongoing education and support to drive adoption of Rigel's products.

Overall, Rigel Pharmaceuticals reported solid growth in Q1 2026, with a focus on expanding its product offerings and advancing its clinical pipeline, while also facing challenges related to market competition and collaboration terminations.